Literature DB >> 32469100

THE PRESENT AND FUTURE OF THE MASS SPECTROMETRY-BASED INVESTIGATION OF THE EXOSOME LANDSCAPE.

Lian Xu1,2, Ryan C Gimple3,4, Wayne Bond Lau5, Bonnie Lau6, Fan Fei7, Qiuhong Shen1,8, Xiaolin Liao7, Yichen Li9, Wei Wang1, Ying He2, Min Feng2, Hong Bu10, Wei Wang1, Shengtao Zhou1.   

Abstract

Exosomes are critical intercellular messengers released upon the fusion of multivesicular bodies with the cellular plasma membrane that deliver their cargo in the form of extracellular vesicles. Containing numerous nonrandomly packed functional proteins, lipids, and RNAs, exosomes are vital intercellular messengers that contribute to the physiologic processes of the healthy organism. During the post-genome era, exosome-oriented proteomics have garnered great interest. Since its establishment, mass spectrometry (MS) has been indispensable for the field of proteomics research and has advanced rapidly to interrogate biological samples at a higher resolution and sensitivity. Driven by new methodologies and more advanced instrumentation, MS-based approaches have revolutionized our understanding of protein biology. As the access to online proteomics database platforms has blossomed, experimental data processing occurs with more speed and accuracy. Here, we review recent advances in the technological progress of MS-based proteomics and several new detection strategies for MS-based proteomics research. We also summarize the use of integrated online databases for proteomics research in the era of big data.
© 2020 John Wiley & Sons Ltd. Mass Spec Rev. © 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  cancer; exosomes; mass spectrometry

Year:  2020        PMID: 32469100     DOI: 10.1002/mas.21635

Source DB:  PubMed          Journal:  Mass Spectrom Rev        ISSN: 0277-7037            Impact factor:   10.946


  6 in total

Review 1.  Mass Spectrometry Approaches Empowering Neuropeptide Discovery and Therapeutics.

Authors:  Krishna D B Anapindi; Elena V Romanova; James W Checco; Jonathan V Sweedler
Journal:  Pharmacol Rev       Date:  2022-07       Impact factor: 18.923

Review 2.  Emerging roles of exosome-derived biomarkers in cancer theranostics: messages from novel protein targets.

Authors:  Jiongjia Cheng; Xiaofeng Wang; Xuechun Yuan; Guangxiang Liu; Qian Chu
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

3.  MALDI-MS-based biomarker analysis of extracellular vesicles from human lung carcinoma cells.

Authors:  Zitong Yu; Chao Zhao; Shi Hu; Huitao Zhang; Wenbo Li; Renjie Zhang; Qian Luo; Hui Yang
Journal:  RSC Adv       Date:  2021-07-21       Impact factor: 4.036

4.  Circulating exosomal mRNA signatures for the early diagnosis of clear cell renal cell carcinoma.

Authors:  Xing He; Feng Tian; Fei Guo; Fangxing Zhang; Huiyong Zhang; Jin Ji; Lin Zhao; Jingyi He; Yutian Xiao; Longman Li; Chunmeng Wei; Caihong Huang; Yexin Li; Feng Zhang; Bo Yang; Huamao Ye; Fubo Wang
Journal:  BMC Med       Date:  2022-08-25       Impact factor: 11.150

Review 5.  Osteoimmunomodulation role of exosomes derived from immune cells on osseointegration.

Authors:  Yunchao Xiao; Yanshu Ding; Jingwen Zhuang; Ruoyue Sun; Hui Sun; Long Bai
Journal:  Front Bioeng Biotechnol       Date:  2022-08-19

Review 6.  Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular.

Authors:  Weipu Mao; Keyi Wang; Zonglin Wu; Bin Xu; Ming Chen
Journal:  J Exp Clin Cancer Res       Date:  2021-09-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.